Google Alert - finance

	finance As-it-happens update ⋅ March 7, 2023
	NEWS
	ETF Daily News Investors await details on Protagonist's oral interleukin win Vantage It has taken years and multiple attempts, but Protagonist Therapeutics might finally have an oral drug to rival injectable autoimmune disease therapies. "Might" is the operative word here, however: the company has only said that its Johnson ... Flag as irrelevant
See more results | Edit this alert

You have received this email because you have subscribed to Google Alerts. Unsubscribe | View all your alerts

Receive this alert as RSS feed

Send Feedback